Protocol Ledger

NCT05377047 · Phase III · RECRUITING

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT05377047 sponsored by Vastra Gotaland Region in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-19 Enrollment: 345 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05377047
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)345 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05377047
Protocol FieldVerified Registry Value
NCT IdentifierNCT05377047
Consolidated Lead SponsorVastra Gotaland Region
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment345 participants (ESTIMATED)
Registered Start Date2022-09-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05377047
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->
Haukeland University HospitalBergen, NorwayOpen Hospital Dossier ->
Karolinska University HospitalStockholm, SwedenOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI